Electrophysiological Challenges of Cell-Based Myocardial Repair
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
C ardiovascular diseases remain the major cause of death in the Western world. 1 Stem and progenitor cell (SPC)based therapies in animal models and human trials in recent years have suggested promising therapeutic potential and drawn intense public interest.Possible beneficial mechanisms of cell-based therapies include generation of new and mature ventricular cardiomyocytes (cardiomyogenesis), recruitment of endogenous SPCs for cardiomyogenesis, and salvage of native myocardium through paracrine, angiogenic, and antiapoptotic effects. 2,33][4][5] Here we discuss potential electrophysiological challenges and arrhythmic risks posed by cell therapies designed to replace damaged myocardium.Although adverse outcomes after cell therapies, such as lethal arrhythmias, occurred in early clinical trials of skeletal myoblast transplantation, 5-8 recent clinical trials using various sources of SPCs, novel modes of cell delivery, better cell selection, and different timing of cell transplantation did not show any significant increase in arrhythmic incidence.It is tempting to conclude on this basis that cell-based therapies are "safe" and nonarrhythmogenic (reviewed in References 2 and 4); however, the negligible production of new cardiomyocytes documented for many SPCs employed makes it difficult to extrapolate their safety records toward future trials in which substantial numbers of new cardiomyocytes might be generated or introduced.Clinical trials to test cardiomyocyte replacement (cardiomyogenesis), long a goal of SPC-based therapy, are bound to take place in the near future, thanks to many investigators who are developing technologies for efficient generation of cardiomyocytes from SPCs and for increasing their retention after transplantation.In weighing the benefits of replacement therapies, we should not overlook the fact that SPC-derived cardiomyocytes exhibit variable electrophysiological properties and are typically immature compared with adult cardiomyocytes (see below).This immaturity of primitive SPC-derived cardiomyocytes remains a major hurdle toward developing safe cell therapies.In anticipation of improved cardiomyogenesis in future cell therapies, we will review here developmental and electrophysiological challenges, common to all SPC-derived cardiomyocytes, that need to be resolved to improve the maturation of primitive SPC-derived cardiomyocytes and to avoid unwanted risks of increasing arrhythmic incidence (proarrhythmia) after transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart
Ott, H. C., Matthiesen, T. S., Goh, S.-K., Black, L. D., Kren, S. M., Netoff, T. I., & Taylor, D. A. (2008) · Nature Medicine · doi:10.1038/nm1684 · Cited by 2,650
Basic Mechanisms of Cardiac Impulse Propagation and Associated Arrhythmias
KLÉBER, A. G., & RUDY, Y. (2004) · Physiological Reviews · doi:10.1152/physrev.00025.2003 · Cited by 1,083
He, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800
Liu, J., Fu, J. D., Siu, C. W., & Li, R. A. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0549 · Cited by 186
PIORKOWSKI, C., KOTTKAMP, H., TANNER, H., KOBZA, R., NIELSEN, J. C., ARYA, A., & HINDRICKS, G. (2005) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2005.00245.x · Cited by 110
Cited by
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
Chong, J. J. H., Yang, X., Don, C. W., Minami, E., Liu, Y.-W., Weyers, J. J., Mahoney, W. M., Van Biber, B., Cook, S. M., Palpant, N. J., et al. (2014) · Nature · doi:10.1038/nature13233 · Cited by 1,408
Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939
Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts
Shiba, Y., Fernandes, S., Zhu, W.-Z., Filice, D., Muskheli, V., Kim, J., Palpant, N. J., Gantz, J., Moyes, K. W., Reinecke, H., et al. (2012) · Nature · doi:10.1038/nature11317 · Cited by 768
Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair
Xin, M., Olson, E. N., & Bassel-Duby, R. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3619 · Cited by 514
Epicardial FSTL1 reconstitution regenerates the adult mammalian heart
Wei, K., Serpooshan, V., Hurtado, C., Diez-Cuñado, M., Zhao, M., Maruyama, S., Zhu, W., Fajardo, G., Noseda, M., Nakamura, K., et al. (2015) · Nature · doi:10.1038/nature15372 · Cited by 489
Self-citationMenasché, P., Vanneaux, V., Hagège, A., Bel, A., Cholley, B., Parouchev, A., Cacciapuoti, I., Al-Daccak, R., Benhamouda, N., Blons, H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.047 · Cited by 456
Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes
Feyen, D. A. M., McKeithan, W. L., Bruyneel, A. A. N., Spiering, S., Hörmann, L., Ulmer, B., Zhang, H., Briganti, F., Schweizer, M., Hegyi, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107925 · Cited by 400
“The diastolic potential and upstroke velocity values exceeded typical values for pluripotent stem cell-derived CMs and iPSC-CMs in RPMI (Figure S4D) and approached those in normal adult ventricular myocytes, which are typically near −85 mV and ~200–300 V/s, respectively (Chen et al., 2009).”
Self-citationLiu, B., Lee, B. W., Nakanishi, K., Villasante, A., Williamson, R., Metz, J., Kim, J., Kanai, M., Bi, L., Brown, K., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0229-7 · Cited by 371
Zhang, Q., Jiang, J., Han, P., Yuan, Q., Zhang, J., Zhang, X., Xu, Y., Cao, H., Meng, Q., Chen, L., et al. (2011) · Cell Research · doi:10.1038/cr.2010.163 · Cited by 367
Cell therapy trials for heart regeneration — lessons learned and future directions
Menasché, P. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0013-0 · Cited by 272
Mihic, A., Li, J., Miyagi, Y., Gagliardi, M., Li, S.-H., Zu, J., Weisel, R. D., Keller, G., & Li, R.-K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.052 · Cited by 248
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues
Feric, N. T., & Radisic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.019 · Cited by 247
Zhu, W.-Z., Xie, Y., Moyes, K. W., Gold, J. D., Askari, B., & Laflamme, M. A. (2010) · Circulation Research · doi:10.1161/circresaha.110.223917 · Cited by 228
Alginate Formulations: Current Developments in the Race for Hydrogel-Based Cardiac Regeneration
Cattelan, G., Guerrero Gerbolés, A., Foresti, R., Pramstaller, P. P., Rossini, A., Miragoli, M., & Caffarra Malvezzi, C. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00414 · Cited by 152
Recent insights into factors affecting remnant lipoprotein uptake
Williams, K. J., & Chen, K. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328338cabc · Cited by 91
Treatment of Oxidative Stress with Exosomes in Myocardial Ischemia
Liu, Y., Wang, M., Liang, Y., Wang, C., Naruse, K., & Takahashi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041729 · Cited by 42
Update on cardiac stem cell therapy in heart failure
Donndorf, P., Strauer, B.-E., & Steinhoff, G. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32834fe969 · Cited by 18
“It might therefore be necessary to upgrade the methods of arrhythmia tracking, using, for example, implantable event recorders or implantable cardioverter defibrillator [31].”
Method
Metadata
- Authors
- Chen, H.-S. V., Kim, C., & Mercola, M.
- Venue
- Circulation
- Published
- 2009-12-15
- Volume
- 120
- Issue
- 24
- Pages
- 2496-2508
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2136122531
- Cited by
- 111
- References
- 5
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.